Maternal Syphilis Screening Recommendations Stand Firm

Maternal Syphilis Screening Recommendations Stand Firm

The U.S. Preventive Services Task Force (USPSTF) in a recommendation statement published this week in JAMA reaffirmed its highest recommendation for early and universal syphilis screening in pregnancy, which aligns with its 2018 guidance. The recommendation emphasizes screening for all pregnant adolescents and adults at the first prenatal opportunity, regardless of individual risk factors, using both treponemal and non-treponemal tests. The directive is based on high-certainty evidence that syphilis screening during pregnancy provides a substantial …

Read More
Bedtime Antihypertensive Regimens Offer No Special Benefit

Bedtime Antihypertensive Regimens Offer No Special Benefit

A Canadian trial published in JAMA  involving 3,200 primary care patients (56.4% female; median age, 67 years) evaluated the timing of antihypertensive medication administration and found no difference in morning vs bedtime dosing. Over a median follow-up of 4.6 years, bedtime dosing was found to be safe but offered no additional cardiovascular benefit. Rates of major cardiovascular events or death were similar between groups (2.3 vs 2.4 per 100 patient-years; adjusted hazard ratio 0.96, 95% …

Read More
Newly Approved HPV Home Testing Kits Launch Next Month

Newly Approved HPV Home Testing Kits Launch Next Month

The Food and Drug Administration has approved the first at-home, vaginal-sample self-collection device for cervical cancer screening, according to a press release from the device manufacturer, Teal Health. As an alternative to in-office sampling and screening, the home collection method also includes virtual access to providers who prescribe the sample-collection kit, review the results from the lab, and answer patient questions. After the patient receives the at-home kit and collects the samples using a wand …

Read More
Live Zoster Vaccine Demonstrates Heart Benefits

Live Zoster Vaccine Demonstrates Heart Benefits

According to a study in the European Heart Journal, the live zoster vaccine may provide cardiovascular benefits in addition to preventing herpes zoster. In a cohort study in Korea involving over 1 million individuals aged 50 years and older, vaccination was associated with a 23% reduction in the risk of major cardiovascular events—including stroke, heart failure, and coronary heart disease—over a period of 8 years. Live zoster vaccination was associated with lower risks of overall …

Read More
Newly Approved DHE Nasal Powder Treats Migraine

Newly Approved DHE Nasal Powder Treats Migraine

The Food and Drug Administration (FDA) has approved dihydroergotamine (DHE) nasal powder 5.2 mg for the acute treatment of migraine in adults with or without aura. The new product is currently the only DHE nasal powder available for this indication, according to a press release from manufacturer Satsuma. Clinical studies demonstrated that the formulation offers rapid absorption, quick attainment of high plasma DHE concentrations, and sustained levels over time. It was generally well tolerated both …

Read More
Pediatric Deaths Climb in the Current ‘Highly Severe’ Flu Season 

Pediatric Deaths Climb in the Current ‘Highly Severe’ Flu Season 

According to the last weekly report from the Centers for Disease Control and Prevention (CDC), the current influenza season in the United States has resulted in the highest number of pediatric deaths since the H1N1 influenza pandemic in 2009–2010. As of the week ending April 26, 2025, at least 216 influenza-associated pediatric deaths have been reported—well above the 207 deaths recorded during the last flu season and especially concerning given that the season isn’t quite …

Read More
One Dose of HPV Vaccine Could Be Enough

One Dose of HPV Vaccine Could Be Enough

A large-scale clinical trial conducted by the National Cancer Institute found that one dose of an HPV vaccine is just as protective against infection as the traditional 2-dose regimen. The randomized study, which enrolled more than 20,000 girls aged 12 to 16 years, compared the effectiveness of 1 and 2 does of the bivalent Cervarix (GlaxoSmithKline) vaccine and the 9-valent Gardasil 9 (Merck) vaccine. Participants were assigned to receive either dosing regimen, and both groups …

Read More
Clinicians Vary in Antiviral Recommendations For Children With Flu

Clinicians Vary in Antiviral Recommendations For Children With Flu

In practice, just under half of pediatricians (49.5%) follow national recommendations from the American Academy of Pediatrics (AAP) for use of the antiviral oseltamivir for children hospitalized with influenza, according to survey results published in Pediatrics. The survey polled 787 physicians from 5 specialties among 7 children’s hospitals in the United States from March 2024 to June 2024. AAP recommends that all children hospitalized for flu receive oseltamivir. Knowing about AAP recommendations increased the pediatricians’ …

Read More
Is There Room For More Antiviral Prescribing in Urgent Care?

Is There Room For More Antiviral Prescribing in Urgent Care?

A multi-state study analyzed prescribing patterns of influenza antiviral medications in emergency departments (ED) and urgent care (UC) centers and found that many high-risk adults (those with cardiovascular disease, renal disease, weakened immune systems, or individuals older than 70 years) with positive influenza virus test results do not receive antiviral treatment, which the authors believe could help reduce the risk of complications. As published in Clinical Infectious Diseases, researchers found that slightly more than half …

Read More
RSV Vaccine Protection Wanes Quickly For Older Adults

RSV Vaccine Protection Wanes Quickly For Older Adults

The protection offered by the respiratory syncytial virus (RSV) vaccine wanes over time for older adults, even with a booster dose 1 year after initial vaccination, according to a study published in Lancet Respiratory Medicine. This clinical trial of nearly 25,000 participants in 17 countries is one of the first studies measuring the efficacy of the relatively new RSV vaccine over subsequent seasons for those aged 60 years or older. Research data shows that efficacy …

Read More